Lupus Patients with Highly Active Disease Responded Well to Atacicept in Short- and Long-term, Phase 2 Trial Shows
News
Systemic lupus erythematosus (SLE) patients with highly active disease responded well to treatment with atacicept at 150 mg each week — especially those on continuous treatment for about one ... Read more